Balugrastim biosimilar - Jiangsu T-mab BioPharma

Drug Profile

Balugrastim biosimilar - Jiangsu T-mab BioPharma

Alternative Names: GW-003

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jiangsu T-mab BioPharma
  • Class Chemoprotectants; Granulocyte colony-stimulating factors
  • Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Neutropenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Neutropenia(Chemotherapy-induced) in China (SC, Injection)
  • 01 Mar 2016 Jiangsu T-Mab Biopharma initiates enrolment in a phase I trial in Neutropenia (Chemotherapy-induced) in China (SC) (NCT02725606)
  • 01 Dec 2015 Jiangsu T-Mab Biopharma completes a phase I trial in Neutropenia (Chemotherapy-induced) in China (SC) (NCT02156388)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top